Cardiac & Bronchodialators Flashcards

(45 cards)

1
Q

Digitalis MOA

A

-inhibits Na/K ATPase in myocardium = ↑Na = ↑activity of Na/Ca exchanger = ↑Ca
-Leads to: ↑ino, ↑EF, ↓preload, ↓AV node conduction, ↓SA node automaticity

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Digitalis therapeutic index

A

0.8-2 ng/ml
toxic > 2.4

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Digitalis SE

A

-arrhythmias (Vfib, AV block)
-↓QT
-cardiotoxic (↑risk w/ ↓K)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Digitalis drug interactions

A

-quinidine
-CCB
-NSAIDS
-amiodarone
-BB
-diuretics

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Digitalis and electrolytes

A

-↓K = ↑dig binding to Na/K ATPase = ↑therapeutic & toxic effects
-↑Ca = ↑digitalis-induced ↑Ca = Ca overload & digitalis-induced arrhythmias
-↓Mg = sensitizes heart to digitalis-induced arrhythmias

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Digitalis Contraindications

A

-↓K
-WPW
-AV block
-renal dysfx
-harmful in pt w/HSS

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

What sympathomimetics are not metabolized by reuptake and MAO & COMT

A

-isoproterenol & dobutamine (COMT only)
-ephedrine (liver, mostly excreted renal unchanged)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Epinephrine receptor & dosing

A

B1>B2, a1
0.01-0.2 mcg/kg/min
1-20 mcg/min

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

NE receptor & dosing

A

a1, B1 > B2
0.01-0.2 mcg/kg/min
4-16 mcg/min

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Dopamine receptor & dosing

A

B1>B2, a1
2-20 mcg/kg/min

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Isoproterenol receptor & dosing

A

B1 > B2
0.015-0.15 mcg/kg/min
1-5 mcg/min

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Dobutamine receptor & dosing

A

B1>B2>a1
2-20 mcg/kg/min

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Ephedrine receptor & dosing

A

a, B indirect
bolus 5-25 mg IV
up to 50 mg IM

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Isoproterenol clinical effect

A

Pure beta agonist
- ↑ HR, contractility, CO
-↓ PVR, DBP
-↑MVO2 demand while ↓ O2 supply

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Dobutamine clinical effect

A

Selective B1 agonist
-↑ contractility, CO, cAMP, Ca in SR
-↓ PVR (B2)
-↓ LV filling pressure –> ↑coronary BF
-stimulates SA, AV nodal automaticity

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

PDE inhibitor MOA

A

↑cAMP & ↑cGMP

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

Clinical indication for PDE 3 vs 4 vs 5

A

-PDE3 = ↑ cAMP & ↑ cGMP (milrinone, cilostazol, amrinone) = inodilators
-PDE4 = ↑ cAMP (roflumilast, apremilast, ibudilast) = help w/ inflammatory states
-PDE5 = ↑ cGMP (sildenafil, tadalafil, vardenafil) = pulm vasodilation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

PDE inhibitor SE

A

-block plt aggregation
-ventricular arrhythmias
-HA
-HoTN
-flushing

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

Inhaled beta-agonist MOA

A

b2 agonist = ↑cAMP = ↓Ca; stabilizes mast cell

20
Q

Inhaled beta-agonist SE

A

-tremor
-↑HR
-hyperglycemia
-↓K
-↓Mg
-dysrhythmias

21
Q

Inhaled muscarinic antagonist MOA

A

M3 antagonist = ↓IP3 = ↓Ca

22
Q

Inhaled muscarinic antagonist short vs long acting

A

-ipratropium (short)
-tiotropium (long)

23
Q

Methylxanthines (theophylline, aminophylline) MOA

A

PDEi = ↑cAMP & ↑cGMP; inhibit leukotriene; adenosine receptor antagonist

24
Q

Dose based SE for Methylxanthines

A

> 20 mcg/ml: N/V/D, HA, insomnia
30 mcg/ml: sz, arrhythmias, CHF

25
Nonselective vs selective alpha antagonist
Non: phenoxybenzamine, phentolamine a1: -zosin a2: yohimbine
26
Phentolamine dose
bolus: 1-5 mg infusion: 0.1-0.2 mg/min
27
Beta antagonist SE
-heart block -HF -AV block -sinus arrest -HoTN -bronchospasm (asthma)
28
What beta antagonist are not metabolized by the liver
Esmolol (hydrolysis of RBCe) Atenolol (renal)
29
Labetalol
-a1, B1, B2 (1a:7B) -mixed blockade↓ PVR, ABP w/o reflex tachy -IV peak 5 min -Dose: 0.1-0.25 mg/kg q 10 min
30
Class I antidysrhythmic SE
-cinchonism -cardiotoxicity -arterial embolism -hypersensitivity rxn
31
Class I antidysrhythmic MOA
-depresses phase 0 -mixed effects on phase 3 repolarization
32
Class IA antidysrhythmic
-Quinidine -procainamine -disopyraminde -moricizine
33
Class IB antidysrhythmic
-Lidocaine -Tocainide -Mexiletine
34
Class IC antidysrhythmic
-Flecanide -Propafenone
35
Class II antidysrhythmic
Beta blockers
36
Class II antidysrhythmic MOA
-slows phase 4 depolarization in SA node
37
Class III antidysrhythmic MOA
-prolongs phase 3 repolarization (↑QT) -↑effective refractory period
38
Class III antidysrhythmic SE
-pulmonary/thyroid/CV/dErm toxic -optic neuropathy -corneal microdeposits
39
Class III antidysrhythmic
↓K -amiodarone -sotalol ibutilide -dofetilide -bretylium
40
Class IV antidysrhythmic
CCB: -Verapamil -Diltiazem
41
Class IV antidysrhythmic MOA
↓conduction velocity through AV node
42
Adenosine MOA
↓AV node conduction d/t K efflux (hyperpolarizes); 6 > 12 mg
43
Non-dihydropyridines vs Dihydropyridines
**Non-dihydropyridines** -verapamil, diltazem - Target myocardium = ↓coronary vascular resistance, ↓ino, ↓dromo, ↓chrono **Dihydropyridine** - -dipine -Targets vascular smooth muscle = ↓SVR
44
CCB SE
-inhibit inflow of Ca into cells of cardiac & vascular smooth muscle
45
CCB Drug Interactions
-potentiate NMB & LA -vasoplegic synd -may ↑dig levels -BB -HoTN, CHF, asystole, high-degree AV block w/ BB and dig